Diabetes mellitus and coronary heart disease

Endocrinology and Metabolism Clinics of North America

Volumn 30, Issue 4, 2001, Pages 857-881

  Wilson, P W F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; DIABETES CONTROL; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 0035173459     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70219-X     Document Type: Article

References (147)

1. The impact of diabetes on survival following myocardial infarction in men versus women: The Framingham Study
2. Management of dyslipidemia in adults with diabetes
3. The UGDP controversy
4. An updated coronary risk profile: A statement for health professionals
5. The pathogenesis of insulin-dependent diabetes mellitus
6. Low-density lipoprotein subclass patterns and risk of myocardial infarction
7. Estimated life expectancy of diabetics
8. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men?
9. Cardiovascular disease in older adults with glucose disorders: Comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria
10. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study
11. Noninvasive assessment of cardiomyopathy in normotensive diabetic patients between 20 and 50 years old
12. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry
13. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions: An autopsy study from the Honolulu Heart Program
14. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
15. Low density lipoprotein particle size and coronary artery disease
16. Non-insulin-dependent diabetes mellitus in minorities in the United States
17. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus: Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM
18. Altered platelet function in diabetes mellitus
19. Diagnosis and management of nephropathy in patients with diabetes mellitus
20. Standardized measures in diabetic neuropathy
21. The pharmacological treatment of hyperglycemia in NIDDM
22. Physical and metabolic characteristics of persons with diabetes
23. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group
24. Platelet function in patients with type 2 diabetes mellitus: The effect of glycaemic control
25. Pharmacologic therapy for type 2 diabetes mellitus
26. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction
27. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
28. Diabetes mellitus: A major risk factor for cardiovascular disease: A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Disease and The American Heart Association
29. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial
30. Whole blood impedance platelet aggregometry and ischemic heart disease
31. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
32. Abnormalities of ambulatory 24-hour heart rate in diabetes mellitus
33. The natural history of diabetic autonomic neuropathy
34. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis
35. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
36. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study)
37. Mortality in non-insulin-dependent diabetes
38. Exogenous insulin administration and cardiovascular risk in non-insulindependent and insulin-dependent diabetes mellitus
39. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
40. The relationship between metabolic control and vascular complications of diabetes mellitus
41. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors
42. Mortality factors in diabetes: A 20 year mortality study
43. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents
44. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
45. Diabetes and decline in heart disease mortality in US adults
46. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993
47. Timolol treatment after myocardial infarction in diabetic patients
48. Lipoprotein(a) and diabetes: An update
49. Management of dyslipidemia in adults with diabetes
50. Coronary heart disease in patients with diabetes
51. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
52. Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: The Wisconsin Epidemiologic Study of Diabetic Retinopathy
53. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?
54. Decrease of lp(a) with improved glycemic control in subjects with insulin-dependent diabetes mellitus
55. Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type 2 diabetes
56. Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM)
57. The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors
58. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
59. Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population
60. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr
61. Forum One: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus
62. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction
63. Trends in CHD in the United States
64. Diabetic retinopathy and cardiovascular disease in type 2 diabetics
65. Lipoprotein metabolism in diabetes mellitus
66. Coronary heart disease prevalence and its relation to risk factors in American Indians
67. Silent myocardial ischemia in patients with diabetes: Who to screen
68. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: Sixth report
69. Incidence and prognosis of unrecognized myocardial infarction
70. Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience
71. Role of diabetes in congestive heart failure
72. Diabetes and cardiovascular risk factors: The Framingham Study
73. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study
74. Fibrinogen and risk of cardiovascular disease
75. Prevalence and incidence of non-insulin-dependent diabetes
76. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults
77. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment
78. Identification of multiple subclasses of plasma low density lipoproteins in normal humans
79. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus
80. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications
81. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
82. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus: The Finnish Studies
83. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland
84. Detection of silent myocardial ischemia in diabetes mellitus
85. Influence of diabetes mellitus on the results of coronary bypass surgery: Follow-up of 212 diabetic patients ten to 15 years after surgery
86. Impact of diabetes on coronary artery disease in women and men: A meta-analysis of prospective studies
87. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
88. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry
89. Change in LDL particle size is associated with change in plasma triglyceride concentration
90. The stages in diabetic renal disease: With emphasis on the stage of incipient diabetic nephropathy
91. Prevention of diabetic renal disease with special reference to microalbuminuria
92. Left ventricular systolic function in middle-aged patients with diabetes mellitus
93. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus
94. Some answers, more controversy, from UKPDS
95. The clinical information value of the glycosylated hemoglobin assay
96. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
97. Screening for asymptomatic coronary artery disease in diabetes
98. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: Assessment by exercise thallium scintigraphy
99. Diabetes-associated mortality in Native Americans
100. On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy
101. Major electrocardiographic abnormalities among American Indians aged 45 to 74 years (the Strong Heart Study)
102. From diagnosis and classification to complications and therapy. DCCT. Part 2. Diabetes Control and Complications Trial
103. Factors associated with avoidance of severe complications after 25 yr of IDDM: Pittsburgh Epidemiology of Diabetes Complications Study I
104. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes
105. Diabetes mellitus: Incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945-1970
106. Calcium antagonists and the diabetic hypertensive patient
107. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infaction
108. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production
109. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
110. Lens changes and the incidence of cardio-vascular events among persons with diabetes
111. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
112. Smoking and other risk factors for coronary heart disease in British civil servants
113. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
114. Unchanged incidence of diabetic nephropathy in IDDM patients
115. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
116. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
117. Insulin resistance is an important determinant of left ventricular mass in the obese
118. Clinical and operative characteristics of patients randomized to coronary artery bypass surgery in the Bypass Angioplasty Revascularization Investigation (BARI)
119. Cardiomyopathy associated with noninsulin-dependent diabetes
120. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with noninsulin-dependent diabetes mellitus in a defined population
121. Comparative features of newly acquired left and right bundle branch block in the general population: The Framingham Study
122. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status
123. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study)
124. The UGDP and insulin therapy
125. Hyperinsulinemia, insulin resistance, and hyperglycemia: Contributing factors in the pathogenesis of hypertension and atherosclerosis
126. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
127. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
128. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis
129. Impact of obesity on neuropathic late complications in NIDDM
130. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
131. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
132. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
133. Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus
134. DNA polymorphisms at the lipoprotein lipase gene are associated with macroangiography in type 2 (non-insulin-dependent) diabetes mellitus
135. Long-term prognosis after myocardial infarction in men with diabetes
136. Myocardial infarction site and mortality in diabetes
137. Diabetes mellitus and coronary heart disease
138. The epidemiology of diabetes mellitus in the elderly: The Framingham Study
139. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study
140. Heart disease and diabetes
141. Diabetes mellitus as a risk factor for acute myocardial infarction in Asians and Europeans
142. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial
143. Human coronary microvessels in diabetes and ischaemia: Morphometric study of autopsy material
144. Coronary heart disease in diabetes mellitus: Three new risk factors and a unifying hypothesis
145. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
146. Diabetic cardiomyopathy